BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9659966)

  • 1. Therapeutic-interchange program for oral histamine H2-receptor antagonists.
    Chase SL; Peterson AM; Wordell CJ
    Am J Health Syst Pharm; 1998 Jul; 55(13):1382-6. PubMed ID: 9659966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
    Quercia RA; Chow MS; Jay GT; Quintiliani R
    Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine.
    Oh T; Franko TG
    Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
    Coppola P
    Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with a two-tiered therapeutic interchange policy.
    Rich DS
    Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Criteria-based DUE aids in selection of preferred agent.
    Drea EJ
    Hosp Formul; 1991 Nov; 26 Suppl D():25-7. PubMed ID: 10136562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic substitution of cimetidine for nizatidine was not associated with an increase in healthcare utilization.
    Good CB; Fultz SL; Trilli L; Etchason J
    Am J Manag Care; 2000 Oct; 6(10):1141-6. PubMed ID: 11184669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
    Segal R; Oh T; Ben-Joseph R; Russell WL
    Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational selection of H2-receptor antagonists for the hospital formulary. Roundtable discussion.
    Keeffe EB; Harper JM; LeMay A; Sherrin TP; Siepler JK
    Hosp Formul; 1991 Nov; 26 Suppl D():13-9. PubMed ID: 10136560
    [No Abstract]   [Full Text] [Related]  

  • 10. Retrospective analysis of formulary restriction demonstrates significant cost savings.
    Wetmore RW; Jennings RH
    Hosp Formul; 1991 Nov; 26 Suppl D():30-2. PubMed ID: 10136564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulary designation of cimetidine as the primary intravenous histamine H2-receptor antagonist.
    Berkowitz HS
    Am J Hosp Pharm; 1992 Jan; 49(1):134-5. PubMed ID: 1349201
    [No Abstract]   [Full Text] [Related]  

  • 12. Decision analysis applied to selection of histamine H2-receptor antagonists for the formulary.
    Calvo MV; Fruns I; Domínguez-Gil A
    Am J Hosp Pharm; 1990 Sep; 47(9):2002-6. PubMed ID: 1977316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in prescribing patterns of intravenous histamine2-receptor antagonists results in significant cost savings without adversely affecting patient care.
    Fudge KA; Moore KA; Schneider DN; Sherrin TP; Wellman GS
    Ann Pharmacother; 1993 Feb; 27(2):232-7. PubMed ID: 8094986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
    Kitrenos JG; Brown DR; Letting DJ; Rotella DL
    Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interactions of H2-receptor antagonists.
    Bachmann KA; Sullivan TJ; Jauregui L; Reese J; Miller K; Levine L
    Scand J Gastroenterol Suppl; 1994; 206():14-9. PubMed ID: 7863246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-column field-amplified sample stacking in capillary electrophoresis for the determination of cimetidine, famotidine, nizatidine, and ranitidine-HCl in plasma.
    Wu SM; Ho YH; Wu HL; Chen SH; Ko HS
    Electrophoresis; 2001 Aug; 22(13):2717-22. PubMed ID: 11545397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of H2-receptor antagonists in the treatment of duodenitis.
    Laguzzi E; Blago MR; Girmania P; Sitar G
    Tokai J Exp Clin Med; 1992 Jul; 17(2):63-6. PubMed ID: 1359681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shifting physician prescribing to a preferred histamine-2-receptor antagonist. Effects of a multifactorial intervention in a mixed-model health maintenance organization.
    Brufsky JW; Ross-Degnan D; Calabrese D; Gao X; Soumerai SB
    Med Care; 1998 Mar; 36(3):321-32. PubMed ID: 9520957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using multiple pharmacoeconomic methods to conduct a cost-effectiveness analysis of histamine H2-receptor antagonists.
    McCoy S; Blayney-Chandramouli J; Mutnick A
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S8-12. PubMed ID: 9872687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
    Schachtner JM; Guharoy R; Medicis JJ; Newman N; Speizer R
    Am J Health Syst Pharm; 2002 Mar; 59(6):529-33. PubMed ID: 11908245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.